An investigational monoclonal antibody targeting interferon beta (IFNβ) led to rapid and pronounced reductions in disease activity in adults with dermatomyositis, a randomized phase II study showed.

Children with a rare, debilitating muscle disease could benefit from the findings of new research by experts at UCL and Great Ormond Street Hospital (GOSH). For the study, published in Annals of the ...

Roivant and partner Priovant Therapeutics said on Wednesday that their experimental drug for a rare disease affecting skin and muscles has shown promising results in a late-stage clinical trial.